Equities

Changchun BCHT Biotechnology Co

688276:SHH

Changchun BCHT Biotechnology Co

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)22.05
  • Today's Change-0.01 / -0.05%
  • Shares traded1.71m
  • 1 Year change-63.85%
  • Beta--
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments4378621,150
Total Receivables, Net1,600992772
Total Inventory199192241
Prepaid expenses342826
Other current assets, total(25)(16)0.06
Total current assets2,2452,0582,190
Property, plant & equipment, net2,0851,6421,439
Goodwill, net------
Intangibles, net347382380
Long term investments2086169
Note receivable - long term------
Other long term assets31--27
Total assets5,0464,2844,175
LIABILITIES
Accounts payable172564
Accrued expenses984150
Notes payable/short-term debt2000
Current portion long-term debt/capital leases------
Other current liabilities, total879651635
Total current liabilities1,015717749
Total long term debt000
Total debt2000
Deferred income tax0.981.11--
Minority interest------
Other liabilities, total106.238.34
Total liabilities1,026724757
SHAREHOLDERS EQUITY
Common stock413413413
Additional paid-in capital1,8201,7781,771
Retained earnings (accumulated deficit)1,8191,3801,240
Treasury stock - common------
Unrealized gain (loss)(32)(11)--
Other equity, total----(5.75)
Total equity4,0203,5603,418
Total liabilities & shareholders' equity5,0464,2844,175
Total common shares outstanding413413413
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.